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Abstract
Background: Systemic sclerosis (SSc) and primary biliary 
cholangitis (PBC) are autoimmune diseases that may 
occur concomitantly and are both strongly associated 
with disease-specific autoantibodies. This study investi-
gated the prevalence and fine specificity of PBC-specific 
serology (PBC-Ab) and associations with the SSc-subtypes 
and SSc-specific antibodies as well as the association with 
cholestatic liver enzymes. Furthermore, three different 
techniques for the detection of PBC-Ab were compared.
Methods: Serum of 184 Belgian SSc patients with a known 
SSc-antibody profile, was analyzed for PBC-Ab (anti-
mitochondrial antibodies [AMA], anti-Gp210, anti-Sp100 
and anti-PML) using indirect immunofluorescence (IIF) 
analysis on human epithelioma-2000 (HEp-2000) cells 
(ANA-IIF, Immunoconcepts) and liver-kidney-stomach 
tissue sections (IIF-LKS) (Menarini), and a line immuno-
blot (LB) (EuroImmun). Alkaline phosphatase/γ-glutamyl 
transferase (ALP/GGT) were evaluated at time of first sam-
pling (t0) and after 3 years of follow-up (t3).
Results: PBC-Ab were present in 13% of patients and sig-
nificantly correlated with centromere antibodies (anti-
CENP-B), but not correlated with the limited cutaneous 
SSc subgroup (lcSSc). The most frequent reactivities were 
AMA (11%, with 9% AMA-M2) and Sp-100 antibodies (5%), 
showing a major overlap. There was no relevant asso-
ciation between the presence of PBC-Ab and ALP or GGT 
elevation at t0 nor at t3. Detection of AMA with IIF-LKS 
is comparable to LB. ANA-IIF screening was less sensitive 
compared to LB.
Conclusions: A wide range of PBC-Ab is detectable in SSc 
in the absence of cholestatic liver enzyme elevations, even 
after 3  years of follow-up. However, as these antibodies 
may precede PBC-disease up to 10 years further prospec-
tive follow-up of our cohort will be necessary.
Keywords: alkaline phosphatase; antimitochondrial anti-
bodies; primary biliary cholangitis; systemic sclerosis.
Introduction
Systemic sclerosis (SSc) and primary biliary cholangitis 
(PBC) are chronic auto-immune diseases that may occur 
concomitantly. SSc is a rare connective tissue disease 
characterized by a triad of fibrosis of the skin and internal 
organs, vasculopathy and immunological abnormalities. 
The disease has a very heterogeneous clinical presenta-
tion and patients are classically subclassified based on 
the extent of skin thickening into limited cutaneous SSc 
(lcSSc), affecting skin distal from the elbow and knee 
joints, and diffuse cutaneous SSc (dcSSc), affecting skin of 
the face, trunk and both proximal and distal extremities [1]. 
PBC is a cholestatic liver disease with chronic destructive 
non-suppurative cholangitis of the intrahepatic bile ducts, 
which may progress, via a fibrotic stage, to cirrhosis in a 
minority of patients. Both diseases are strongly associated 
with the presence of disease-specific  autoantibodies [2, 3].
In SSc, antinuclear antibodies (ANA) are present in 
about 95% of patients [4]. In routine practice, serum is 
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screened for the presence of ANA by indirect immuno-
fluorescence (IIF) on human epithelioma-2(000) (HEp-
2(000)) cells. After a positive ANA IIF result, further 
elaboration for the specific antigenic targets (anti-ENA) 
mostly reveals one of the following antibodies: anti-
centromere (anti-CENP-B), anti-DNA topoisomerase I 
(anti-Scl70), anti-fibrillarin, anti-PM/Scl or anti-RNA 
polymerase III (anti-RNAPIII). These autoantibodies 
are highly SSc-specific and mutually exclusive. Further-
more, these antibodies are of prognostic importance due 
to their association with specific disease manifestations, 
i.e. anti-CENP-B positivity is linked to lcSSc and pulmo-
nary arterial hypertension, anti-Scl70 positivity is linked 
to dcSSc and interstitial lung disease and anti-RNAPIII 
is linked to dcSSc, malignancies and scleroderma 
renal crisis [5]. Today, several commercial multiparam-
eter assays exist to detect these SSc-specific antibodies 
(SSc-Ab).
Antimitochondrial antibodies (AMA) are the serologi-
cal hallmark of PBC, with mostly AMA-M2 type (target-
ing the proteins of the alpha-keto acid dehydrogenase 
complexes) considered clinically relevant. AMA occur 
in 90–95% of PBC patients and may be present years 
before disease onset. Furthermore, 90% of asymptomatic 
patients positive for AMA express histological features 
compatible with PBC [6, 7]. The guidelines of the European 
Association for the Study of the Liver (EASL) prescribe 
that patients with AMA are at risk for developing PBC and 
recommend yearly follow-up of the cholestatic liver tests 
alkaline phosphatase (ALP) and γ-glutamyl transferase 
(GGT) for these patients [3]. In routine practice, screening 
for AMA is mostly performed by IIF on liver-kidney-stom-
ach (LKS) tissues. In the case of a characteristic fluores-
cence pattern, the presence of AMA-M2 is confirmed with 
a specific immunoassay. Additionally, the presence of 
AMA may be suspected if a coarse granular filamentous 
staining throughout the cytoplasm is observed in the ANA 
IIF analysis (ICAP pattern AC-21) [8]. Other PBC-specific 
antibodies (PBC-Ab) include antibodies against Sp100, 
Gp210 and PML [9]. Sp100 and PML are nuclear proteins 
associated with a “multiple nuclear dots” pattern when 
examined by IIF on HEp-2(000) cells (ICAP pattern AC-6) 
[8]. Gp210 may be visible as a membranous pattern (ICAP 
pattern AC-12) [8]. Similar as for serological diagnosis of 
SSc, different commercial multiparameter immunoassays 
are available to detect the different PBC-Ab. Moreover, 
some of these assays detect both SSc-and PBC-specific 
ANA in parallel.
The association between PBC and SSc is described 
repeatedly in the literature. The prevalence of SSc in 
PBC-patients is estimated at around 2–18%, while the 
frequency of PBC disease in SSc-patients varies around 
2–10% [10–15]. The reported coexistence of SSc and PBC-
specific autoantibodies is higher and fluctuates between 
13% and 21% [13, 16–18]. Although liver disease is not a 
characteristic finding for the disease, it is not a rare obser-
vation in SSc patients, with PBC considered the main 
cause of liver diseases in SSc patients [15]. Table 1 gives an 
overview of the different studies published regarding the 
prevalence and characteristics of PBC-Ab and PBC disease 
in SSc patients.
Historically, AMA detection was often not included in 
the serological routine work-up of SSc patients’ normal 
liver function tests. However, more recently, since the 
introduction of multiparameter assays with parallel detec-
tion of SSc- and PBC-specific ANA, AMA-M2 are frequently 
detected in SSc patients (even in the absence of a charac-
teristic IIF pattern on LKS or HEp-2[000]). Nevertheless, 
until today, it is unclear if this PBC-specific serology in SSc 
patients is predictive for the development of PBC disease 
and which SSc patients have a higher risk for developing 
PBC. This knowledge would be of particular importance 
to improve timely diagnosis and guide early treatment of 
SSc-patients with ursodeoxycholic acid (UCDA) [3].
The aim of our study was to investigate the prevalence 
and fine specificity of PBC-specific serology as well as 
associations with the SSc-subtypes and SSc-specific anti-
bodies in a large Belgian cohort of SSc patients. Associa-
tions between the presence of PBC-specific serology and 
biochemical markers for cholestatic liver disease were 
also evaluated (up to 3  years after detection of the anti-
bodies). Furthermore, we compared three different tech-
niques for the detection of PBC-Ab: IIF on HEp-2000 cells, 
IIF on LKS tissue sections for AMA and a line immunoas-
say for AMA-M2 and the other PBC-specific auto-antibod-
ies Gp210, Sp100 and PML.
Materials and methods
Patients and samples
All consecutive SSc patients included in the SSc unit of Ghent Univer-
sity Hospital (Ghent, Belgium) having a minimal of 3 years’ follow-up 
data available after the time of serum sampling or who were still in 
follow-up at the Rheumatology department were included (n = 184). 
All patients fulfilled the preliminary classification criteria of the 
American College of Rheumatology (ACR) and/or the LeRoy and 
Medsger criteria for early SSc and/or the new 2013 ACR/European 
League Against Rheumatism (EULAR) SSc classification criteria [19–
21]. Approval was obtained by the Ghent University Hospital Ethics 
Committee (amendment 2018/0353) and all patients signed informed 
consent. The diagnosis of PBC was made according to the EASL 
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practice guidelines [3]. None of the patients were on UCDA treatment 
at time of serum sampling (t0). Three years after sampling (t3), one 
patient received UCDA treatment.
Auto-antibody detection
Serum of all patients was analyzed for SSc- and PBC-specific anti-
bodies. IIF on HEp-2000 cells (Immunoconcepts, Sacramento, CA, 
USA) was used to screen for ANA (ANA-IIF) and was considered posi-
tive at a titer ≥1:40. Interpretation of ANA patterns occurred follow-
ing the International Consensus on ANA Patterns (ICAP) guidelines 
[8]. IIF on rodent LKS tissue sections (IIF-LKS) was performed for the 
detection of AMA using a serum screen dilution of 1:40 (Menarini, 
Florence, Italy). The presence of SSc-specific antibodies was evalu-
ated with the Euroline SSc profile (IgG) immunoblot (EuroImmun, 
Lübeck, Germany), which detects antibodies directed against Ro52, 
anti-Scl70, CENP-A, CENP-B, RNA polymerase III subunits 11 and 155 
(anti-RNAPIII/11 and anti-RNAPIII/155), fibrillarin, Th/To and PM-Scl 
Table 1: Overview of different publications regarding the prevalence and characteristics of PBC antibodies in SSc patients.
  Study   Number of SSc 
patients
  PBC antibody 
assays
  Prevalence of PBC disease and/
or antibodies in the SSc cohort
  Statistical associations and other 
findings
1.   Assassi et al. 
[12]
  817   AMA: IIF HEp-2 and 
MIT3 ELISA
Anti-Sp100:ELISA
Anti-Gp210: ELISA
  2% (16/817) PBC disease+
12% (101/817) PBC antibody+
 2% (16) AMA IIF+
 7% (56) MIT3+
 3% (26) Sp100+
 0.4% (3) Gp210+
  –  Patients with PBC were 
significantly older and had 
longer disease duration
–  PBC-disease subgroup 
significantly associated with 
anti-CENP-B positivity, but not 
with lcSSc subgroup
–  Association of anti-Sp100 with 
CENP-B antibodies
–  Association of anti-CENP-B and 
anti-Scl70 with higher levels 
of ALP
2.   Norman et al. 
[17]
  52   AMA: MIT3 ELISA
Anti-Sp100: ELISA
Anti-Gp210: ELISA
  15% (8/52) PBC antibody+
 13% (7) MIT3+
 2% (1) Sp100+
  –  No association of PBC-
antibodies with gender, age, 
SSc subgroup, SSc antibodies, 
prevalence of pruritus, the 
presence of other autoimmune 
conditions or liver parameters
–  No anti-Gp210 positivity
3.   Mytilinaiou 
et al. [16]
  37   AMA: IIF HEp-2,  
LKS en MIT3 ELISA
Anti-Sp100:ELISA
  13% (5/37) PBC antibody+
 13% (5) MIT3+
  –  No elevated liver parameters in 
the five PBC antibody positive 
subjects
–  five subjects were only MIT3 
positive, no positivity for anti-
Sp100 or AMA on IIF HEp-2 or 
LKS
4.   Imura-Kumada 
et al. [13]
  225   AMA: MIT3 ELISA
Anti-Sp100:ELISA
Anti-Gp210: ELISA
  10% (22/225) PBC disease+
21% (48/225) PBC antibody+
 16% (37) MIT3+
 6% (13) Sp100+
 1% (3) Gp210+
  –  6% (13/225) suspected of 
PBC disease but  PBC antibody 
negative
–  patients with PBC were 
associated with CENP-B and 
lcSSc
5.   Cavazzana 
et al. [18]
  201   AMA: IIF LKS and  
MIT3 ELISA
Anti-Sp100:ELISA
Anti-Gp210: ELISA
  4% (8/201) PBC disease+
21% (43/201) PBC antibody+
 18% (36) MIT3+
 3% (5) Sp100+
 0.5% (1) Gp210+
  –  Association of PBC-antibodies 
with lcSSc, anti-CENP-B and 
elevated ALP levels
–  AMA detected by IIF on LKS 
showed lower sensitivity but 
higher specificity compared to 
MIT3 ELISA
6.   Mari-Alfonso 
et al. [15]
  1572   /   4% (67/1572) PBC disease+   – No antibody detection
ALP, alkaline phosphatase; AMA, anti-mitochondrial antibodies; IIF, indirect immunofluorescence; LKS, liver kidney stomach tissue sections; 
lSSc, limited systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; PBC, primary biliary cholangitis; SSc, systemic sclerosis.  
Bold text PBC disease+ indicates PBC disease present; Bold text PBC antibody+ indicates PBC-specific serology positive.
Florin et al.: Primary biliary cholangitis-related serologic profile in systemic sclerosis patients      419
subunits 75 and 100 (anti-PM/Scl75 and anti-PM/Scl100). In addi-
tion, all samples were analyzed for PBC-Ab with the Euroline Profile 
Autoimmune Liver Diseases (IgG) line immunoblot (EuroImmun), 
which detects following antibodies: AMA-M2, M2-3E, Sp100, PML and 
Gp210. This line immunoblot (LB) combines both the native 74 kDa 
E2-antigen of the M2-pyruvate dehydrogenase complex (PDC) (most 
targeted antigen in PBC), as well as the recombinant M2-3E fusion 
protein, which contains the immunogenic domains of E2-subunits 
of the 3 M2-enzymes PDC, branched chain oxo-acid dehydrogenase 
complex (BCOADC) and the oxoglutarate dehydrogenase complex 
(OGDC), in order to increase the sensitivity for AMA-M2 antibodies. 
M2-3E is similar to the hybrid MIT3 antigen ELISA used in previous 
publications [12, 17, 18]. Results of the LBs were digitized using a cali-
brated flatbed scanner, and absolute signal intensities were imported 
by a computer program for further analysis (EUROLineScan, Euro-
Immun). Interpretational criteria as proposed by Bonroy et al. were 
applied for the SSc-specific antibody analysis [2]. Interpretation of 
the PBC antibody LB was performed according to manufacturer’s 
instructions (positive if signal intensity >10 units [U]).
Other laboratory analyses
The relationship between the presence of PBC-Ab and ALP and GGT 
levels at the time of sampling (t0) as well as 3 years after sampling 
(t3) were investigated (t3 data available in 138/184 patients). ALP and 
GGT levels were defined as elevated when concentrations were above 
the (gender-dependent) upper limit of normal (ULN). For statistical 
processing of data, SPSS Statistics 25 (SPSS Inc.) was used. Continu-
ous variables were converted into z-scores in case gender-dependent 
differences were expected [22]. Statistical significance was accepted 
at p < 0.05.
Results
Patients and samples
In total, 184 SSc patients were included in this study (33 
dcSSc, 124 lcSSc and 27 limited SSc [lSSc] patients). Sev-
enty-five percent of patients were female and the mean 
age was 58 years (range 21–86).
Prevalence and fine specificity of PBC-Ab and 
relation with SSc-subtype and SSc-specific 
antibodies
Antibodies against at least one PBC-specific antigen 
(detected by LB or by IIF-LKS) were found in 13% of 
SSc patients (23/184). AMA (detected on LB and/or IIF-
LKS) were present in 11% (20/184) of sera, with AMA-M2 
(including M2-3E reactivity) observed in 9.2% (17/184) (for 
more details see comparison LKS and LB). Anti-Sp100 was 
detected in 5% of patients (9/184) and the antibod-
ies against Gp210 and PML were only detected in one 
patient each (<1%). Multiple reactivities were present in 
up to 30% of PBC-serology positive cases, with 66% of 
the anti-Sp100 positive cases also showing AMA-M2 or 
M2-3E reactivity (see Figure 1). A more detailed overview 
of the reactivities on LB is given in Supplementary File 1. 
 Chi-square testing showed no statistically significant dif-
ferences for gender and age between both PBC-Ab positive 
and negative subgroups (Table 2). In addition, no statisti-
cal difference could be shown when comparing patients 
with dcSSc and lcSSc (Fisher exact, p = 0.569). However, 
there was a significant association between PBC-Ab posi-
tivity and the presence of anti-CENP-B antibody (Fisher 
exact, p = 0.042).
Figure 1: Number of patients out of a total of 184 SSc patients 
that tested positive for one or more of the following PBC-specific 
antibodies: AMA, anti-Gp210, anti-Sp100 and anti-PML.
Table 2: Comparison of demographic and laboratory data in SSc 
patients negative and positive for PBC-specific autoantibodies.
 
 
PBC-specific autoantibodies  p-Value
Negative  Positive
Mean age, years (SD)   57.2 (13.4)  60.9 (11.0)  0.202
Gender (M/F)   1/3  1/11  0.054
SSc typea       0.569
 dcSSc   30/33 (91%)  3/33 (9%) 
 lcSSc   106/124 (86%)  18/124 (14%) 
 lSSc   25/27 (93%)  2/27 (7%) 
SSc-specific antibodiesb       0.042
 No SSc-specific Ab   61/67 (91%)  6/67 (9%) 
 Anti-Scl70   28/29 (97%)  1/29 (3%) 
 Anti-CENP-B   66/80 (83%)  14/80 (17%) 
 Anti-PM/Scl   1/1 (100%)  0/1 (0%) 
 Anti-RNAPIII   5/6 (83%)  1/6 (17%) 
  Anti-Scl70 and anti-
CENP-B
  0/1 (0%)  1/1 (100%) 
aOnly dcSSc and lcSSc were included for statistical analysis (Fisher 
exact test). p-Values in bold are considered statistically significant 
(p < 0.05); bComparison of patients with and without anti-CENPB; 
dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited 
cutaneous systemic sclerosis; lSSc, limited systemic sclerosis.
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Relation between PBC-Ab and cholestatic 
liver enzymes
The presence of PBC-Ab was correlated with the choles-
tatic liver enzymes ALP and GGT (paired analysis avail-
able for n = 136). We observed no statistical difference 
in ALP levels between the PBC-Ab positive and negative 
subgroup (Mann-Whitney U, p = 0.098) at the time of 
sampling (t0), nor 3 years thereafter (t3) (Mann-Whitney 
U, p = 0.220) (see Figure 2A). In addition, paired analysis 
of t0 and t3 data of PBC-Ab positive patients showed no 
significant increase in ALP levels (Wilcoxon signed rank 
test, p = 0.163) (Figure 3A). Two of the patients with PBC 
positive serology showed elevated ALP levels at t0 (ALP 
titers 1.3 ×  ULN and 1.05 ×  ULN). At t3, ALP levels normal-
ized for one patient without PBC diagnosis (from 1.05 ×  
ULN towards 0.9 ×  ULN), whereas for the other patient 
(with AMA positivity detected by IIF-LKS and LB [also 
positive for anti-SP100, anti-PML and anti-M3-3E]), ALP 
levels remained elevated (1.5 ×  ULN). In that patient, PBC 
was diagnosed but he was not treated with UCDA at the 
moment of sampling.
In contrast, for GGT, we observed a statistical dif-
ference in levels between the PBC-Ab positive and nega-
tive subgroup at t0 (Mann-Whitney U, p = 0.033), and at 
t3 (Mann-Whitney U, p = 0.006) (Figure 2B). In addition, 
paired analysis of t0 and t3 data of PBC-serology positive 
patient showed a significant difference in GGT levels (Wil-
coxon signed rank test, p = 0.034) (Figure 3B). Nevertheless, 
this is due to a lowering of GGT levels after 3 years of follow-
up and thus is not clinically relevant in the development 
of PBC disease. Detailed analysis of PBC serology positive 
patients showed four cases with elevated GGT levels at t0, 
with normalization in one of them at t3. However, elevation 
of GGT may be seen in a number of different diseases and 
is not considered specific enough for diagnosis of PBC [3].
PBC-specific serology detected with different 
methods
A comparison between the results for AMA as detected by 
IIF-LKS and LB showed a good agreement with a kappa 
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Figure 2: Box plot of the liver enzymes ALP (A) and GGT (B) for PBC-
antibody positive and negative subgroups at the time of sampling 
(t0) and after 3 years of follow-up (t3).
A statistical difference in GGT (expressed as z-scores) (panel B) but 
not in ALP levels (panel A) between both subgroups at both time 
points was observed (Mann-Whitney U testing, *p-values <0.05 were 
considered statistically significant).
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Figure 3: Line chart for ALP (A) and GGT (B) levels from PBC antibody 
positive patients at time of sampling (t0) and after 3 years (t3). 
Paired analysis of t0 and t3 data of PBC-serology positive patients 
showed a significant difference in GGT levels (expressed as z-scores) 
(panel B) but not in ALP levels (panel A) (Wilcoxon signed rank test, 
*p-values <0.05 were considered statistically significant).
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value of 0.77 (95% confidence interval 0.60–0.93). The 
contingency table is given in Table 3. Four samples were 
positive for AMA on LB but negative on IIF-LKS. All four 
samples had reactivity against AMA-M2 (range signal inten-
sities 17–72 U), while only two showed reactivity against 
M2-3E (52 and 56 U). The three LB negative/IIF LKS positive 
samples showed weak to moderate intensity scoring on IIF.
We also evaluated the performance of IIF on HEp-
2000 cells for detection of the different PBC-Ab. The 
typical AMA pattern (AC-21) was only observed in 25% of 
AMA positive samples (LKS and/or LB positive), but when 
it was observed it was highly specific (100%). In contrast, 
we observed no multiple nuclear dots (AC-6) or nuclear 
membrane pores (AC-12) patterns in our cohort, hence 
presence of antibodies against Sp100, PML or Gp210 could 
not be predicted.
Discussion
The prevalence of PBC-Ab in SSc disease varies according 
to the literature from 15 to 21% [13, 16–18]. Depending on 
the study, only AMA or AMA in combination with the other 
PBC-Ab were evaluated in SSc patients [2, 10, 12, 13, 15]. In 
our very SSc cohort study, using an LB that detects AMA, 
Sp100, Gp210 and PML reactivities, we found a slightly 
lower prevalence of 13%. This discrepancy may be due to 
differences in techniques used to detect PBC-Ab or popu-
lation-based differences. Indeed, in contrast to previous 
studies, we included an lSSc-subgroup. When this sub-
group was excluded, PBC-antibody positivity increased 
to 15%. AMA were most frequently detected (in 11% of 
patients), followed by anti-Sp100 (5%), anti-Gp210 (0.5%) 
and anti-PML (0.5%), which is similar to previous publica-
tions [13, 16–18].
A statistically significant association was demon-
strated between PBC positive serology and the presence 
of anti-CENP-B. However, we observed no statistical asso-
ciation between the presence of PBC-Ab and the lcSSc 
subtype. These findings are in agreement with what was 
previously published by Assassi et al. [12]. Other studies, 
based on smaller cohorts, reported an association with 
both CENP-B antibodies as well as the lcSSc-subgroup 
[13, 18]. In line with the findings of Norman et al., we also 
observed no association between age and gender and the 
presence of PBC-Ab [17].
In both SSc and PBC, the appearance of disease spe-
cific antibodies may precede disease development [6, 
23]. Within this context, we evaluated the relationship 
between the presence of PBC-Ab and cholestatic liver 
enzymes both at the time of serum sampling, as well as 
3 years thereafter. To the best of our knowledge, this was 
the first study to investigate the liver parameters in SSc 
patients after multiple years of follow-up. We could not 
demonstrate a statistically significant difference for ALP 
levels between both subgroups at both time points, nor in 
the paired analysis between t0 and t3 for the PBC serology 
positive samples. However, as AMA may be present up to 
10 years before development of PBC, it may be necessary 
to repeat this statistical analysis at a later time point. In 
contrast, we observed a statistically significant difference 
for GGT levels, both at time of sampling and after 3 years, 
with slightly higher levels in the PBC antibody positive 
subgroup. However, according to the EASL guidelines, 
GGT is not specific enough for diagnosis of PBC as differ-
ent other liver diseases may provoke a GGT elevation [3]. 
Earlier studies of Norman et al. and Mytilinaiou et al. did 
not find a significant difference between PBC serology and 
the liver enzymes ALP and GGT [16, 17]. In contrast, the 
study of Cavazzana et al. showed that there was an asso-
ciation between the presence of PBC-Ab and elevated ALP 
levels [18]. None of these studies however investigated 
liver parameters multiple years after diagnosis.
As today, the classical sequence of screening for 
PBC-Ab by LKS followed by confirmation using a spe-
cific assay is often abandoned in routine practice, we 
performed a comparison between both methods (LB and 
LKS). We observed a good agreement between both for 
AMA, an observation in line with the data of Han and 
colleagues [24]. Nevertheless, it must be mentioned that 
in about 4% of our cohort (or 35% within the positive 
samples) PBC-specific serology was only detected in one 
of both strategies. Moreover, the finding of LB positive 
samples without LKS IIF positivity (23% on LKS) suggests 
that LKS IIF cannot be used as screening. As we observed 
no association between the specific cholestatic liver 
enzyme ALP (both at t0 and t3) and the presence of PBC-Ab 
detected by either of the techniques, we cannot make firm 
Table 3: 2 × 2 contingency table for detection of antimitochondrial 
antibodies (AMA) by indirect immunofluorescence (IIF) on rodent 
liver-kidney-stomach (LKS) tissue sections and by line immunoblot 
(LB).
IIF on LKS tissue sections
AMA present AMA absent Total
LBa
 AMA present 13 4 17
 AMA absent 3 164 167
 Total 16 168 184
aPresence of AMA defined by reactivity for AMA-M2 and/or M2-3E.
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conclusions about the preferable first line method or the 
need for parallel analysis with both techniques. The LB for 
detection of PBC-Ab contains both the native E2-antigen of 
the M2-PDC enzyme, which is the most targeted antigen 
in PBC, and the recombinant M2-3E fusion protein, which 
contains the immunogenic domains of E2-subunits of the 
three M2-enzymes PDC, BCOADC and OGDC, in order to 
increase the sensitivity for AMA-M2 antibodies. However, 
taken into account the M2-3E fusion protein, LB identifies 
only one extra patient (1/20) (see Supplementary File 1), 
suggesting no major added value in including this fusion 
protein in the LB. Our data showed that different PBC-spe-
cific reactivities may occur concomitantly in SSc patients. 
Considering this overlap, we found that the additional 
detection of antibodies targeting Sp100, Gp210, PML and 
M2-3E retrieved five extra patients compared to single 
detection of AMA-M2 (2.7% within the SSc cohort, 25% of 
all LB positive samples).
Additionally, we investigated if IIF on HEp-2000 cells 
could be used as a screening technique for PBC-Ab. We 
found an excellent specificity (100%) but a poor sensitiv-
ity 25%) for the detection of AMA. None of the samples 
with Gp210, Sp100 or PML antibodies were detected 
by IIF (n = 7). Therefore, IIF does not seem appropri-
ate as a screening technique for PBC-Ab. Muratori et  al. 
showed that ANA detected by IIF were present in half of 
PBC patients, but this study included also other fluores-
cence patterns not specific for PBC disease (e.g. anti-SSA 
pattern, anti-CENP-B pattern, etc.) [25].
Our study has some limitations. We did not perform 
echography or liver biopsy, nor did we correlate PBC 
serology with clinical symptoms for all samples, thereby 
making it impossible to make a final diagnosis of PBC 
disease in the whole SSc cohort. As mentioned, as AMA 
may be present up to 10 years before development of PBC, 
the follow up time of 3 years in this study is limited. As this 
is a prospective cohort, we plan to repeat the analysis after 
6 or 10 years of follow-up.
We conclude that, in our SSc study cohort, PBC-Ab 
were present in 13% and significantly correlated with 
anti-CENP-B positivity. The most frequent reactivities 
were AMA (11%, with 9% AMA-M2) and Sp-100 antibodies 
(5%), showing a major overlap. We observed comparable 
detection of AMA on IIF and LB with no added value for 
the detection of anti-M2-3E, while ANA IIF screening was 
less sensitive compared to LB for the detection of the other 
PBC-Ab (Gp210, Sp100 and PML). There was no relevant 
association between presence of PBC-specific serology and 
cholestatic liver enzymes up to 3 years follow up. However, 
as AMA may precede PBC-disease up to 10 years, further 
prospective follow-up of our cohort will be necessary.
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